Dr. Tyna Moore · 2026-05-14 · Tyna Moore (host), Amie Hornaman

What Doctors Don't Tell You About Your Thyroid | Dr. Amie Hornaman

26 research-tied claims examined: 4 contradicted 7 overstated 4 context 9 supported 2 unverified

Contradicted by research

0:31:07 Tyna Moore (host)contradictedhigh

The DSM-IV states that if antidepressants do not work, clinicians should consider Cytomel (T3).

"In the DSM-4, when you apply an antidepressant to a patient and it doesn't work—like usually SSRI will be like first line, you may give them an MAO inhibitor, you apply those antidepressants and they'll, you know, they'll stack them sometimes—and it doesn't work, it actually says to consider Cytomel and make sure that you address the T3" (said at 0:31:07)

The host claims that the DSM-IV explicitly directs clinicians to consider Cytomel (triiodothyronine/T3) when antidepressant treatment fails. This statement misrepresents the manual. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) is strictly a diagnostic taxonomy used to classify and define criteria for psychiatric disorders; it does not contain pharmacological treatment guidelines, clinical prescribing algorithms, or medication recommendations. Clinical practice guidelines and clinical trials evaluate T3 augmentation strategies in patients who meet DSM-IV diagnostic criteria for major depressive disorder (e.g., PMID 16483669), but the DSM-IV manual itself does not instruct clinicians to prescribe Cytomel or any other drug.

contradicts: T3 augmentation of SSRI resistant depression. (Journal of affective disorders 2006) · cited 92x in the literature
"Patients who fulfilled the DSM-IV criteria for non-psychotic major depression, able to give informed consent, and failed to show satisfactory antidepressant response after a minimum of six weeks adequate treatment were recruited." (abstract, methods, passage verified)
pubmed full study (doi)

0:34:10 Amie Hornamancontradictedhigh

Eighty to ninety percent of the population has Hashimoto's thyroiditis.

"I think it's safe to say like 80 to 90% of the population has Hashi." (said at 0:34:10)

The speaker's claim that 80% to 90% of the population has Hashimoto's thyroiditis is contradicted by epidemiological evidence. A comprehensive global systematic review and meta-analysis of 48 studies covering over 22 million participants found that the overall adult prevalence of Hashimoto's thyroiditis is approximately 7.5% (95% CI: 5.7% to 9.6%), with regional estimates ranging from 5.8% to 14.2%. Even when considering thyroid autoantibody seroprevalence in general populations, figures remain far below the claimed 80% to 90%.

contradicts: Global prevalence and epidemiological trends of Hashimoto's thyroiditis in adults: A syste… (Frontiers in public health 2022) · cited 267x in the literature
"A total of 11,399 studies were retrieved, of which 48 met the research criteria... Furthermore, there are two projects involving 19 countries and 22,680,155 participants. The prevalence of Hashimoto's thyroiditis was 7.5 (95%CI 5.7-9.6%), while in the low-middle-income group the prevalence was 11.4 (95%CI 2.5-25.2%)." (abstract, results)
pubmed full study (doi)

0:47:18 Amie Hornamancontradictedlow

Hypothyroidism or low thyroid function impairs the effectiveness of GLP-1 receptor agonist medications.

"Thyroid's low and slow, GLP-1 won't work. People are wasting money." (said at 0:47:18)

Clinical evidence directly contradicts the claim that hypothyroidism prevents GLP-1 receptor agonists from working. In a retrospective case-control study evaluating weight loss with the GLP-1 receptor agonist liraglutide, individuals with hypothyroidism on stable levothyroxine therapy achieved significant and comparable weight loss relative to matched controls without thyroid disease (-10.8% vs. -8.9%, P = 0.940), with similar proportions reaching ≥5% total body weight loss (79.2% vs. 71.0%, P = 0.248). Baseline TSH levels within the normal reference range did not predict or limit weight loss outcomes.

contradicts: Weight and body composition outcomes with liraglutide in individuals with well-treated hyp… (PloS one 2025) · cited 3x in the literature
"Liraglutide leads to clinically meaningful and comparable weight loss in individuals with well-treated hypothyroidism and those without thyroid disease. Body composition changes were also similar between groups." (abstract, conclusions, passage verified)
pubmed full study (doi)

1:05:07 Tyna Moore (host)contradictedhigh

A study showed that women with subclinical hypothyroidism have approximately a 56% increased risk of dying from a heart attack.

"He showed a study in women in particular, if they were subclinical hypothyroid, meaning their labs looked normal, but symptomology was there, like 56% increased risk for dying of a heart attack." (said at 1:05:07)

The speaker misdefines subclinical hypothyroidism and inaccurately characterizes its diagnostic findings. Subclinical hypothyroidism is strictly defined as a laboratory diagnosis in which thyroid-stimulating hormone (TSH) is elevated while free thyroxine (T4) remains within the normal reference range, regardless of symptoms (patients are frequently asymptomatic). It does not mean that lab tests are normal. Regarding cardiovascular risk, major population studies in postmenopausal women, such as the Rotterdam Study (PMID 10681281), found that subclinical hypothyroidism ( elevated TSH with normal free T4) was an independent risk factor associated with an increased prevalence of myocardial infarction (odds ratio 2.3; 95% CI, 1.3 to 4.0) and aortic atherosclerosis (odds ratio 1.7; 95% CI, 1.1 to 2.6). Because the host's claim fundamentally misstates the diagnostic criteria of the condition, the overall assertion is contradicted.

contradicts: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardia… (Annals of internal medicine 2000) · cited 1356x in the literature
"Subclinical hypothyroidism was defined as an elevated thyroid-stimulating hormone level (>4.0 mU/L) and a normal serum free thyroxine level (11 to 25 pmol/L [0.9 to 1.9 ng/dL])." (abstract, methods, passage verified)
pubmed full study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.